曲妥珠单抗联合化疗治疗HER2阳性乳腺癌经济性的系统综述OA
Pharmacoeconomic Evaluation on Trastuzumab in Adjuvant Breast Cancer Therapy for HER2-Positive Breast Cancer:A Systematic Review
目的：对曲妥珠单抗联合化疗治疗HER2阳性乳腺癌的药物经济学进行系统分析。方法：计算机检索PubMed、Sci-enceDirect、SpringerLink等数据库2003～2013年间已发表的药物经济学文献，按照一定标准进行筛选，根据药物经济学方法，进行系统综述。结果：曲妥珠单抗治疗的增量成本效果比（ICER）值，美国在34307～126933美元/质量调整生命年（QALY），瑞典为35975～52753欧元/QALY，挪威需要多付出8148…查看全部>>
Objective: To systematically evaluate the pharmacoeconomic vaule of Trastuzumab in adjuvant breast cancer therapy for HER2-positive breast cancer.Methods: A systematic literature search of cost-effectiveness studies on Trastuzumab in adjuvant breast cancer therapy for HER2-positive breast cancer published from 2003 to 2013 was carried out in PubMed, Science Direct, Springer Link and some other database.The studies were screened according to inclusion criteri…查看全部>>
刘永军;马林超
中国药科大学，江苏南京211198中国药科大学，江苏南京211198
医药卫生
曲妥珠单抗HER2阳性乳腺癌药物经济学综述
TrastuzumabHER2-positive breast cancerPharmacoeconomicsReview
《中国药物评价》 2014 (4)
243-248,6
评论